白三烯拮抗剂孟鲁斯特钠联合舒利迭治疗老年哮喘的疗效

Leukotriene antagonist montelukast sodium combined with seretide for senile asthma

目的探讨白三烯拈抗剂孟鲁斯特钠联合舒利迭治疗老年哮喘的临床疗效。方法将我院老年哮喘患者62例随机分为两组，两组患者均给予常规治疗。对照组31例，在常规治疗基础上给予舒利迭雾化吸入治疗（每日2次，每次250μg）；实验组31例，在常规治疗基础上给予自三烯拮抗剂孟鲁斯特钠（每晚1次，每次10mg）联合舒利迭雾化吸人（每日2次，每次250gg）治疗，比较两组患者的治疗效果。结果两组患者治疗后的症状和肺部功能均有明显效果（总有效率分别为90．32％、70．97％），其中实验组患者治疗后的临床症状与肺部功能改善更佳[一秒量（FEV1．0）：（2．24±0．41）LVS．（1．92±0．27）L，一秒率（FEV1．0％）：（0．45±0．11）vs．（0．37±0．09），用力吸气峰流速（PEF）：（4．55±0．12）L／sVS．（4．03±0．27）L／s]，两组比较差异有统计学意义（P〈0．05）。结论白三烯拮抗剂孟鲁斯特联合吸入舒利迭治疗老年哮喘具有较好的治疗效果，值得在临床应用。

Objective To investigate the efficacy of leukotriene antagonist montelukast sodium combined with seretide in the treatment of senile asthma. Methods 62 elderly patients with asthma were randomly divided into two groups, and then received conventional treatment plus inhaled seretide of 250 μg twice daily （ 51 patients, control group ） or plus the same seretide combined with leukotriene antagonist montelukast sodium of 10 mg per night （ 31patients, study group ）. The efficacy was compared between the two groups. Results After treatment, symptoms were markedly relieved and lung function was significantly improved in both groups （ 90.32% vs. 70.97% for the total effectiveness rate） symptom relief and improvement in lung function were more significant in the study group [FEV1.0（2.24 ± 0.41 ） Lvs. （ 1.92 ± 0.27） L, FEV1.0%： （0.45 ± 0.11 ） vs. （0.37 ± 0.09）, PEF： （4.55 ± 0.12） L/ s vs. （ 4.03 ± 0.27 ） L/s ; P 〈 0.05]. Conclusions Combination therapy with leukotriene antagonist montelukast sodium and seretide for senile asthma has a better efficacy and is worth being applied clinically.